Advertisement

Topics

Turning Point Prices IPO, Raising $166M to Test Cancer Drugs

11:24 EDT 17 Apr 2019 | Xconomy

Turning Point Therapeutics raised more than $166 million in its IPO, pricing at the top of its range and putting nearly 2 million more shares into the public markets than it had initially planned. Strong demand ahead of the offering prompted the company, which is developing targeted cancer drugs for patients that have developed resistance […]

Original Article: Turning Point Prices IPO, Raising $166M to Test Cancer Drugs

NEXT ARTICLE

More From BioPortfolio on "Turning Point Prices IPO, Raising $166M to Test Cancer Drugs"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...